MOLECULAR MARKERS FOR METASTASIS OF COLORECTAL CANCER

根治性手术切除胆囊癌患者的不良结局 直肠癌和结肠癌是由于局部复发或出现 最初是隐蔽的远处转移。分子方法学提供了新的 评估手术切缘状况和转移的方法 原发肿瘤的表型。聚合酶链式反应与克隆入 用于进一步扩展的噬菌体载体允许检测来自 数千个非肿瘤细胞中只有一个突变癌细胞。 代表性差异分析(RDA)提供了识别 并对可能作为肿瘤预后标志物的扩增进行表征。 在这个项目中要检验的假设是： L。手术切缘显微镜下隐匿的肿瘤细胞。 直肠癌患者可以通过分子遗传分析来检测， 从而作为复发的标志。 2.原发结直肠癌中扩增的基因是贫乏的标志 预后。 我们这个项目的具体目标是： L。评价癌旁组织和盆腔组织中ras和p53基因的突变 直肠根治性切除术后冲洗标本采集 癌症。分子遗传学结果将与组织病理学相关 发现、复发和存活率。 2.将代表性差异分析(RDA)应用于配对 转移性和非转移性原发结直肠癌。RDA探头 检测扩增将被克隆、作图并用于搜索 靶基因。扩增结果将作为预后指标进行评估。

Adverse outcome in patients who undergo curative surgical resection of rectal and colonic carcinoma results from local recurrence or emergence of initially occult distant metastases. Molecular methodologies offer new approaches to evaluate the status of resection margins and the metastatic phenotype in primary tumors. Polymerase chain reaction with cloning into bacteriophage vectors for further expansion permits detection of DNA from one mutant cancer cell among thousands of non-neoplastic cells. Representational difference analysis (RDA) provides the ability to identify and characterize amplifications which may be prognostic markers in tumors. The hypotheses to be tested in this project are: l. Microscopically occult neoplastic cells at the surgical margins of rectal cancer patients can be detected by molecular genetic analysis, thereby serving as markers for recurrence. 2. Amplified genes in primary colorectal carcinomas are markers for poor prognosis. Our specific aims for this project are to: l. Evaluate mutations in ras and p53 genes in margin tissue and pelvic irrigation specimens collected after curative resection of rectal carcinomas. Molecular genetic results will be related to histopathologic findings, recurrence, and survival. 2. Apply representational difference analysis (RDA) to pairs of matched metastatic and non-metastatic primary colorectal carcinomas. RDA probes detecting amplifications will be cloned, mapped, and used to search for target genes. The amplifications will be evaluated as prognostic markers.